Galmed (GLMD) Pharmaceuticals announced that it has signed a binding term-sheet with Entomus s.r.o. for a license agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System formulation that allows absorption of sublingually administrated peptides such as GLP-1. A definitive agreement determining, among other things, the milestones payments and future royalty payments is to be executed within ninety days.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLMD:
- Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers
- Galmed launches VCU collaboration to tackle drug resistance in GI cancers
- Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol
- Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine
- Galmed’s Aramchol Meglumine shows improved results in Part 1 of AM-001 study